can glp 1 cause irritability GLP-1 nausea: How to handle GLP-1s' most common side effect The expanding role of GLP-1
Description
Background With the prevalence of obesity rising in the US, medical management is of increasing importance
Only 40% of 2023 initiators remained on therapy after a year compared to 34% of 2022 initiators and 33% of 2021 initiators
Learn the common causes, treatments, and easy ways to prevent them.
Big move in obesity pharmacotherapy Novo Nordisk has submitted CagriSema to the FDA the first fixed-dose, once-weekly GLP-1 + amylin combination
GLP-1 for lymphedema shows promise in reducing swelling and inflammation
